FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person * Benton Susan					2. Issuer Name and Ticker or Trading Symbol Ocuphire Pharma, Inc. [OCUP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O OCUPHIRE PHARMA, INC., 37000 GRAND RIVER AVE, SUITE 120					3. Date of Earliest Transaction (Month/Day/Year) 09/02/2021						Office	er (give title belo	ow)	Other (specify l	pelow)	
(Street) FARMINGTON HILLS, MI 48335				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	Exect any		(Instr. 8)		ction	4. Securities Acquire (A) or Disposed of (Instr. 3, 4 and 5)		d of (D)	Beneficia Reported	nt of Securities ally Owned Following Transaction(s)		6. Ownership Form:	Beneficial	
				(Month/Day/Ye				V	Amoun	(A) or (D)	Price		(Instr. 3 and 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common	Stock		09/02/2021				P		20,000) A	\$ 4.57 (1)	23,976			D	
Reminder: 1	Report on a s	eparate line to	or each class of secu	Deriv	ative Securi	ies Ac	equire	Pers cont the f	ons what ained in form dis	no resp n this f splays of, or B	orm ar a curre	re not requently valid	OMB con	formation spond unle trol numbe	ess	1474 (9-02)
1 7711 6	2	2.77	24 5 1	` ' '	puts, calls, w		ts, op	1				,	0.00	0.37 1	6 10	11.37.
Security	2. Conversion or Exercise Price of Derivative Security		Year) Execution D	4. Transaction Code Year) (Instr. 8)	Number and		and	Date Exercisable Expiration Date Onth/Day/Year)		An Un Sec	Title and nount of derlying curities str. 3 and		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivate Security Direct (or Indire	Beneficia Ownershi (Instr. 4)	
					Code V	(A)	(D)	Date Exer		Expirat Date	ion Tit	Amount or Number of Shares				

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Benton Susan C/O OCUPHIRE PHARMA, INC. 37000 GRAND RIVER AVE, SUITE 120 FARMINGTON HILLS, MI 48335	X					

Signatures

/s/ Emily J. Johns, by Power of Attorney	09/03/2021		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price represents the weighted average price of the multiple transactions reported on this line. The shares were purchased at prices ranging from \$4.52 to \$4.61. Upon (1) request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.